- Home
- YCBD vs XRTX Comparison
YCBD vs XRTX Comparison
Compare YCBD & XRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YCBD
- XRTX
- Stock Information
- Founded
- YCBD 2015
- XRTX 2011
- Country
- YCBD United States
- XRTX Canada
- Employees
- YCBD N/A
- XRTX N/A
- Industry
- YCBD Biotechnology: Pharmaceutical Preparations
- XRTX Pharmaceuticals and Biotechnology
- Sector
- YCBD Health Care
- XRTX Health Care
- Exchange
- YCBD Nasdaq
- XRTX Nasdaq
- Market Cap
- YCBD 3.2M
- XRTX 3.0M
- IPO Year
- YCBD N/A
- XRTX N/A
- Fundamental
- Price
- YCBD $0.30
- XRTX $0.96
- Analyst Decision
- YCBD
- XRTX
- Analyst Count
- YCBD 0
- XRTX 0
- Target Price
- YCBD N/A
- XRTX N/A
- AVG Volume (30 Days)
- YCBD 965.3K
- XRTX 16.6K
- Earning Date
- YCBD 05-14-2025
- XRTX 05-16-2025
- Dividend Yield
- YCBD N/A
- XRTX N/A
- EPS Growth
- YCBD N/A
- XRTX N/A
- EPS
- YCBD N/A
- XRTX N/A
- Revenue
- YCBD $19,220,238.00
- XRTX N/A
- Revenue This Year
- YCBD $13.00
- XRTX N/A
- Revenue Next Year
- YCBD $10.00
- XRTX N/A
- P/E Ratio
- YCBD N/A
- XRTX N/A
- Revenue Growth
- YCBD N/A
- XRTX N/A
- 52 Week Low
- YCBD $0.21
- XRTX $0.82
- 52 Week High
- YCBD $1.25
- XRTX $3.92
- Technical
- Relative Strength Index (RSI)
- YCBD 47.12
- XRTX 49.57
- Support Level
- YCBD $0.21
- XRTX $0.90
- Resistance Level
- YCBD $0.42
- XRTX $1.10
- Average True Range (ATR)
- YCBD 0.04
- XRTX 0.08
- MACD
- YCBD 0.01
- XRTX -0.00
- Stochastic Oscillator
- YCBD 44.43
- XRTX 38.60
About YCBD cbdMD Inc.
cbdMD Inc is a United States based company. It owns and operates the consumer hemp-based cannabidiol (CBD) brand, cbdMD, Paw CBD as well as ATRx Labs brand of functional mushrooms. The company's product categories include CBD tinctures, CBD gummies, CBD topicals, CBD capsules, CBD oils, and CBD pet products. The firm distributes its products through an e-commerce website, wholesalers, and a variety of brick-and-mortar retailers.
About XRTX XORTX Therapeutics Inc.
XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.